Breast Cancer
Methodology & AI Transparency ⓘ
Breast Cancer Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: What is breast cancer? Breast cancer is a cancer that starts in breast tissue.
- 2 Real-world patient consensus: Federal ICD-10-CM code C90.0 categorizes Breast Cancer under Cancer, Oncology & Supportive Care.
- 3 Typical cash cost range: Primary evaluation for Breast Cancer incorporates tissue biopsy with in Breast Cancer (C90.0: histopathology) and symptom diary review.
- 4 Top reported side effects / signs: Follow-up benchmark in Breast Cancer: maintaining Comprehensive Metabolic & in Breast Cancer (C90.0: Organ Function Panel) within Preserved renal/hepatic clearance (C90.0).
Ask our AI Specialists anything about Breast Cancer
What Is Breast Cancer?
What is breast cancer? Breast cancer is a cancer that starts in breast tissue. It happens when cells in the breast change and grow out of control. New cells grow even when you don't need them, and old cells don't die when they should. These extra cells can form a mass called a tumor. Sometimes the cancer does not spread any further. This is called "in situ." If the cancer spreads outside the breast, the cancer is called "invasive." It may just spread to nearby tissues and lymph nodes. Or the cancer may metastasize (spread to other parts of the body) through the lymph system or the blood.
Pathophysiology, Underlying Causes & Clinical Presentation
Underlying Breast Cancer (code C90.0) is somatic oncogenic driver in Breast Cancer (C90.0: mutations), Cross-referenced with NIH MeSH (Carcinoma, Ductal, Breast, Breast Neoplasms), which Cancer, Oncology & Supportive Care clinicians address while surveilling Comprehensive Metabolic & in Breast Cancer (C90.0: Organ Function Panel) (Preserved renal/hepatic clearance (C90.0)).
Common Symptoms & Clinical Signs
- • Ductal carcinoma , which begins in the cells of the ducts. This is the most common type
- • Lobular carcinoma , which begins in the lobules. It is more often found in both breasts than other types of breast cancer
- • Presentation of Breast Cancer (C90.0): abnormality detected early in Breast Cancer (C90.0: on age-appropriate screening)
- • Secondary Breast Cancer clinical sign: persistent painless lump, in Breast Cancer (C90.0: non-healing ulcer/mole change,)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Breast Cancer Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | C90.0 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Cancer, Oncology & Supportive Care | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Comprehensive Metabolic & in Breast Cancer (C90.0: Organ Function Panel) | Preserved renal/hepatic clearance (C90.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Pathology / Molecular in Breast Cancer (C90.0: Genomic Staging) | Guideline-concordant surveillance (C90.0) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Complete Blood Count in Breast Cancer (C90.0: (ANC, Hemoglobin, Platelets)) | Safe hematologic reserve (C90.0) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Breast Cancer
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Sacituzumab Govitecan Trodelvy • RxCUI 2360534 | FDA Prescription Therapeutic Agent | 92% | $2.6800 | $ 117.04 /mo |
| Docetaxel Docivyx, Beizray • RxCUI 1001405 | Microtubule Inhibitor | 91% | $1.1500 | $ 55.08 /mo |
| Beizray (Docetaxel) Beizray • RxCUI RXN-B83513009 | Microtubule Inhibitor | 74% | $1.6000 | $ 123.70 /mo |
| Trastuzumab-Qyyp Trazimera • RxCUI 2280732 | HER2/neu Receptor Antagonist | 82% | $2.2300 | $ 98.82 /mo |
| Paclitaxel Protein-Bound Particles Paclitaxel 100mg Per Vial • RxCUI 583214 | Microtubule Inhibitor | 84% | $2.0700 | $ 92.33 /mo |
| Tamoxifen Citrate Soltamox, Nolvadex • RxCUI 198240 | Estrogen Agonist/Antagonist | 91% | $0.1255 | $ 8.21 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Breast Cancer)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Effect of concomitant statin treatment in postmenopausal patients with hormone: What a 3,420-Participant Study Found According to this analysis, hydrophilic statins showed a detrimental effect on DFS in the main model, which was attenuated after correction for confounders. ESMO open • 2022-04-15 • Phase III Randomized Trial | N = 3,420 | 96/100 | PMID 35334418 ↗ |
| New Insights on TQB2440 compared with reference pertuzumab for HER2-positive, ER/PgR-negative,: What a 412-Participant Study Found TQB2440 showed equivalent efficacy, comparable safety, PK, and immunogenicity profiles to reference pertuzumab in the neoadjuvant treatment of patients with HER2-positive early or locally advanced breast cancer. ESMO open • 2026-01-15 • Phase III Randomized Trial | N = 412 | 93/100 | PMID 41401771 ↗ |
| New Insights on Lerociclib plus fulvestrant in patients with HR+/HER2- locally advanced or: What a 275-Participant Study Found These findings support lerociclib plus fulvestrant as a treatment option for patients with HR+/HER2- endocrine-resistant advanced breast cancer (ABC). Nature communications • 2025-01-16 • Phase III Randomized Trial | N = 275 | 93/100 | PMID 39820749 ↗ |
| New Insights on Veliparib with carboplatin and paclitaxel in BRCA-mutated advanced breast cancer: What a 509-Participant Study Found Final OS data indicate that the PFS improvement shown in the primary analysis did not translate into an OS benefit. European journal of cancer (Oxford, England : 1990) • 2024-03-15 • Phase III Randomized Trial | N = 509 | 93/100 | PMID 38309017 ↗ |
| Can This Approach Help? Inside the Latest Research on 5-year outcomes of chemotherapy de-escalation in HER2-positive early breast Nature Medicine, Published online: 29 October 2026; doi:10.1038/s41591-026-04723-w A 5-year secondary analysis of the phase 2 PHERGain trial supports the clinical utility of a PET-guided adaptive strategy for treatment de-escalation in HER2-positive early brea Nature Medicine • 2026-10-29 • Peer-Reviewed Journal (Longevity & Biotech) | Multi-cohort | 92/100 | PMID NATURE_MED-4248748391 ↗ |
Breast Cancer Patient Community & “People Like Me” Threads
Filter Breast Cancer community threads and patient logs by age, biological sex, dosage, and treatment duration.